Search

Your search keyword '"Fallani F"' showing total 32 results
Start Over Author "Fallani F" Publisher elsevier bv
32 results on '"Fallani F"'

2. Differential Effect of Everolimus on Progression of Early and Late Cardiac Allograft Vasculopathy in Current Clinical Practice

Author

Masetti, M., primary, Potena, L., additional, Nardozza, M., additional, Prestinenzi, P., additional, Taglieri, N., additional, Saia, F., additional, Pece, V., additional, Magnani, G., additional, Fallani, F., additional, Coccolo, F., additional, Russo, A., additional, Rapezzi, C., additional, Grigioni, F., additional, and Branzi, A., additional

Published
2013
Full Text
View/download PDF

4. 491 Differential Effect of Everolimus and Metabolic Risk Factors on Early vs. Late Progression of Allograft Vasculopathy: Dissecting Two Faces of the Same Disease

Author

Masetti, M., primary, Potena, L., additional, Nardozza, M., additional, Prestinenzi, P., additional, Pece, V., additional, Taglieri, N., additional, Saia, F., additional, Magnani, G., additional, Coccolo, F., additional, Fallani, F., additional, Grigioni, F., additional, and Branzi, A., additional

Published
2012
Full Text
View/download PDF

6. Do I like what I am watching in TV?

Author

Vecchiato, G., primary, Toppi, J., additional, Astolfi, L., additional, De Vico Fallani, F., additional, Bez, Francesco, additional, Cincotti, F., additional, Mattia, D., additional, and Babiloni, F., additional

Published
2011
Full Text
View/download PDF

12. 206 Improvement of Renal Function after Cyclosporine Reduction Is Influenced by Baseline Proteinuria in Patients Converted to Everolimus: Long Term Follow-Up of the Shirakiss Randomized Study

Author

Prestinenzi, P., primary, Potena, L., additional, Bianchi, I.G., additional, Masetti, M., additional, Romani, P., additional, Magnani, G., additional, Fallani, F., additional, Coccolo, F., additional, Russo, A., additional, Grigioni, F., additional, and Branzi, A., additional

Published
2011
Full Text
View/download PDF

28. P36.8 Hypermethods for EEG hyperscannings

Author

Babiloni, F., primary, Cincotti, F., additional, Mattia, D., additional, Marciani, M.G., additional, Bianchi, L., additional, De Vico Fallani, F., additional, Salinari, S., additional, Astolfi, L., additional, and Mattiocco, M., additional

Published
2006
Full Text
View/download PDF

30. Safety and Efficacy of Ezetimibe With Low Doses of Simvastatin in Heart Transplant Recipients

Author

Francesco Fallani, Antonio Russo, Luciano Potena, Antonella Scalone, Fabio Coccolo, Angelo Branzi, Francesco Grigioni, Gaia Magnani, Candida Cristina Quarta, Quarta CC, Potena L, Grigioni F, Scalone A, Magnani G, Coccolo F, Fallani F, Russo A, and Branzi A.

Subjects
Male, Pulmonary and Respiratory Medicine, Simvastatin, medicine.medical_specialty, medicine.medical_treatment, Gastroenterology, Ezetimibe, Internal medicine, medicine, Humans, cardiovascular diseases, Aged, Dyslipidemias, Heart transplantation, Transplantation, biology, business.industry, Anticholesteremic Agents, nutritional and metabolic diseases, Middle Aged, medicine.disease, Hydroxymethylglutaryl-CoA reductase, Treatment Outcome, Endocrinology, Tolerability, HMG-CoA reductase, biology.protein, Azetidines, Heart Transplantation, Drug Therapy, Combination, Female, lipids (amino acids, peptides, and proteins), Surgery, Cardiology and Cardiovascular Medicine, business, Dyslipidemia, medicine.drug
Abstract

Although statins have proven efficacy in lowering lipids and improving survival in heart transplantation (HT) recipients, potential drug interactions may limit efficacy and reduce tolerability. This observational study explored the efficacy and tolerability of ezetimibe (10 mg/day) combined with simvastatin (10 or 20 mg/day) prescribed to HT recipients with intolerance to statins ( n = 11) or inadequate lipid control despite high-dose statins ( n = 14). Substantial reductions in lipid levels were apparent after 2 months (total cholesterol, −22%; low-density lipoproteins, −28%; triglycerides, −31%) and were maintained at 6 months. Reductions were significant in both subgroups of recipients; the vast majority (12 of 14, 85%) of recipients with a history of statins intolerance were able to tolerate ezetimibe plus low-dose simvastatin. This study provides suggestive evidence that treatment with ezetimibe plus low-dose simvastatin is well tolerated by HT recipients and may be effective for treatment of dyslipidemia in HT recipients with statins intolerance or resistance.

Published
2008

31. Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy

Author

Pier Luigi Guidalotti, Mohsen Farsad, Paolo Ciliberti, Letizia Bacchi-Reggiani, Enrica Perugini, Cinzia Pettinato, Claudio Rapezzi, Robin M. T. Cooke, Angelo Branzi, Ornella Leone, Letizia Riva, Francesco Fallani, Fabrizio Salvi, Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, and Rapezzi C.

Subjects
Male, Pathology, medicine.medical_specialty, Heart Diseases, Scintigraphy, Gastroenterology, Diagnosis, Differential, Internal medicine, medicine, AL amyloidosis, Humans, Prealbumin, Radionuclide Imaging, Aged, Diphosphonates, medicine.diagnostic_test, biology, business.industry, Amyloidosis, Reproducibility of Results, nutritional and metabolic diseases, Organotechnetium Compounds, Middle Aged, medicine.disease, Transthyretin, Cardiac amyloidosis, biology.protein, Etiology, Female, Immunoglobulin Light Chains, Radiopharmaceuticals, Differential diagnosis, Cardiology and Cardiovascular Medicine, Amyloid cardiomyopathy, business
Abstract

We investigated the diagnostic accuracy of (99m)Tc-3,3- diphosphono-1,2-propanodicarboxylic acid ((99m)Tc-DPD) scintigraphy for differentiation of monoclonal immunoglobulin light-chain (AL) and transthyretin (TTR)-related cardiac amyloidosis. BACKGROUND: Differential diagnosis between TTR-related and AL amyloidosis is often complex and time-consuming. METHODS: Patients under routine observation with TTR-related/AL systemic amyloidosis and echocardiographic evidence of cardiac involvement were studied with (99m)Tc-DPD scintigraphy. RESULTS: Patients with cardiac involvement of TTR-related (group A; n = 15) and AL (group B; n = 10) etiology were comparable for left ventricular mass and renal function. Heart and heart/whole-body tracer retention were significantly higher (p < 0.05) in group A as compared with group B and with 10 unaffected controls. At visual scoring, cardiac (99m)Tc-DPD uptake was present in all group A patients and absent in all group B patients; thus, using genotyping/immunohistochemistry as the reference technique, the accuracy of (99m)Tc-DPD scintigraphy for distinction of TTR-related and AL etiology was 100%. Cardiac (99m)Tc-DPD uptake was also absent among unaffected controls. Using echocardiography as the reference standard for recognition of cardiac involvement, sensitivity and specificity of scintigraphy were both 100% for group A patients; in group B, sensitivity was 0% and specificity was 100% (accu racy, 50%). Eleven patients with myocardial (99m)Tc-DPD uptake underwent (99m)Tc-methylene diphosphonate ((99m)Tc-MDP) scintigraphy; all patients showed a (99m)Tc-MDP myocardial visual score of 0. CONCLUSIONS: Etiology is a third major cause-in addition to type of organ-involved (soft-tissue/heart) and tracer type-of scintigraphic variability in cardiac amyloidosis. This is a highly relevant consideration for future studies. We conclude that (99m)Tc-DPD scintigraphy is a useful step in the workup of the differential diagnosis of TTR versus AL etiology in patients with documented cardiac amyloidosis.

Published
2005

32. Cardiac resynchronization by pacing: an electrical treatment of heart failure

Author

Claudio Rapezzi, Cristian Martignani, Giuseppe Boriani, Francesco Grigioni, Ivan Corazza, Mauro Biffi, C. Greco, Romano Zannoli, Pietro Bartolini, Angelo Branzi, Francesco Fallani, BORIANI G, BIFFI M, MARTIGNANI C, FALLANI F, GRECO C, GRIGIONI F, CORAZZA I, BARTOLINI P, RAPEZZI C, ZANNOLI R, and BRANZI A.

Subjects
medicine.medical_specialty, Heart disease, Defibrillation, medicine.medical_treatment, Cardiac resynchronization therapy, Sudden death, Internal medicine, medicine, Humans, cardiovascular diseases, Heart Failure, Heart transplantation, medicine.diagnostic_test, Left bundle branch block, business.industry, Cardiac Pacing, Artificial, Hemodynamics, Arrhythmias, Cardiac, medicine.disease, Treatment Outcome, Heart failure, cardiovascular system, Cardiology, Cardiology and Cardiovascular Medicine, business, Electrocardiography
Abstract

Various modalities of cardiac pacing have been proposed in the past to improve hemodynamics, either directly or indirectly. Some of these are conventional ways of cardiac stimulation, others such as biventricular or left ventricular pacing, represent dedicated pacing techniques. Left ventricular and biventricular pacing are successfully applied in those patients with congestive heart failure who have conduction disturbances (i.e. left bundle branch block) as they correct the ensuing intra- and interventricular dyssynchrony. This is the reason why these pacing modalities are described as cardiac resynchronization therapy. According to the results of a series of studies, the cardiac resynchronization therapy seems to have a favourable clinical impact in terms of quality of life, morbidity and hospitalization rate. On-going and future studies should assess the impact of resynchronization therapy on overall mortality and its cost-effectiveness profile in specific subgroups of patients. Other open issues regard (i) the convenience of using biventricular pacing as a pacing-alone therapy or in combination with ventricular defibrillation capability, especially for potential candidates to heart transplantation, and (ii) the ways to identify properly the responders to resynchronization therapy.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results